New pill aims to tame kidney disease in Long-Term trial

NCT ID NCT07616700

Recruiting now Disease control Sponsor: Haisco Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new tablet called HSK39297 for people with IgA nephropathy, a kidney disease that can lead to kidney failure. The trial includes 73 adults who have already taken the drug in a previous study. They will take the tablet once daily for an extended period, with a possible dose increase if needed. The main goal is to check long-term safety and how well the drug controls protein in the urine, a key sign of kidney damage.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: HSK39297 tablets
What this could lead to: If successful, this could point toward a new oral treatment option to control IgA nephropathy and reduce kidney damage over the long term.
What could go wrong: This is an early Phase 2 study with only 73 participants and no placebo group, so results may not confirm effectiveness. Long-term safety is still unknown, and the drug may cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY (IGAN) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

IgA glomerulonephritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IGA NEPHROPATHY (IGAN)

Contacts and locations

Locations

Peking University First Hospital
COMPLETED

Beijing, China
Peking University First Hospital
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.